A 60-year-old woman with type 2 diabetes (HbA1c 8.5% [69 mmol/mol]) and established coronary artery disease is taking maximal tolerated metformin. Her BMI is 34 kg/m² and eGFR is 70 mL/min/1.73 m². According to contemporary Australian guidance, which additional glucose-lowering therapy would be preferred to optimise glycaemic control and reduce cardiovascular risk?